A detailed history of Catalio Capital Management, LP transactions in Uni Qure N.V. stock. As of the latest transaction made, Catalio Capital Management, LP holds 282,940 shares of QURE stock, worth $8.45 Million. This represents 3.05% of its overall portfolio holdings.

Number of Shares
282,940
Previous 417,443 32.22%
Holding current value
$8.45 Million
Previous $5.82 Billion 183.81%
% of portfolio
3.05%
Previous 1.22%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$13.28 - $59.4 $1.79 Million - $7.99 Million
-134,503 Reduced 32.22%
282,940 $16.5 Billion
Q2 2025

Aug 14, 2025

SELL
$8.34 - $17.27 $3.44 Million - $7.13 Million
-412,882 Reduced 49.73%
417,443 $5.82 Billion
Q1 2025

May 15, 2025

SELL
$10.6 - $18.08 $759,468 - $1.3 Million
-71,648 Reduced 7.94%
830,325 $8.8 Billion
Q4 2024

Feb 14, 2025

BUY
$4.54 - $17.73 $4.09 Million - $16 Million
901,973 New
901,973 $15.9 Billion

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $1.4B
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Catalio Capital Management, LP Portfolio

Follow Catalio Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalio Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Catalio Capital Management, LP with notifications on news.